Los Angeles, CA, May 31, 2013 — David Silver, M.D., President and Chief Operating Officer at Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, issued the following statement regarding a University of Michigan study highlighted in Pain Medicine News demonstrating the connection between μ-opioid receptor binding and the brain’s response to fibromyalgia pain: “The University of Michigan study confirms widespread consensus within the medical community that fibromyalgia patients respond poorly to narcotics. Additionally, there is no medical evidence Continue reading →
Los Angeles, CA, November 14, 2011 Targeted Medical Pharma Inc. which develops and sells medical food products through its subsidiary Physician Therapeutics, exhibited product information and technology related to its medical foods addressing pain management and sleep disorders related to Post Traumatic Stress Disorder to over 2000 active and retired United States Military pharmacists, service men and women at the Joint Forces Pharmacy Seminar in Dallas, Texas from October 31-November 3, 2011. Other exhibitors included Takeda, Teva Neuroscience, Pfizer, GlaxoSmithKilne, Endo Pharmaceuticals and Express Scripts. About Targeted Medical Pharma, Inc. Targeted Medical Continue reading →
Grants Cover Theramine® , Sentra PM®, Sentra AM® and GABAdone® Los Angeles, CA, Nov. 1, 2010 /Targeted Medical Pharma Inc. a Specialty Pharma company developing proprietary medical food products distributed through subsidiary Physician Therapeutics announced it has been awarded $733,429.00 in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive Continue reading →
In January of 2009 Physician Therapeutics, a wholly owned subsidiary of Targeted Medical Pharma Inc., initiated A Double Blind randomized controlled trial of single dose Naproxen and an amino acid Medical Food Theramine for the treatment of low back pain. Using 10 national sites over a 28 day period, this study consisted of 127 patients with established back pain. The trial concluded in June of 2009, and the study will be published by the American Journal of Therapeutics in November 2010.